Abstract: The present invention discloses novel chimeric monoclonal antibodies directed against human carcinoembryonic antigen, having antigen-specific variable regions. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are also disclosed. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also described.
Type:
Grant
Filed:
February 16, 1993
Date of Patent:
December 5, 1995
Assignees:
The Dow Chemical Company, National Institutes of Health
Inventors:
Brian B. Gourlie, Mark W. Rixon, Peter S. Mezes, Donald A. Kaplan, Jeffrey Schlom